ABSTRACT BACKGROUND: Omega-3 polyunsaturated fatty acid (n−3 PUFA) metabolism seems
INTRODUCTION
Cardiovascular diseases (CVD) are one of the leading causes of death worldwide.
Carrying the apolipoprotein E epsilon 4 allele (E4+) is one of the most important genetic risk factor of developing age-related chronic diseases such as CVD and Alzheimer's disease (AD) [1] . One environmental factor likely capable of decreasing the risk of CVD and AD is through consumption of omega-3 fatty acids (n−3 PUFA) from fatty fish [2] .
A low balance of n−6/n−3 PUFA seems to be contributing in decreasing the risk of inflammatory-related diseases and may promote heart and brain health [3] . However, E4+ do not seem to be protected against CVD [4] and cognitive decline [5, 6] when consuming n−3 PUFA. Recent evidences suggest that this lack of protection could be related to dysfunction of n−3 PUFA metabolism and kinetics [7, 8] .
In human, there are three isoforms of the apoE protein, namely apoE2, apoE3 and apoE4, resulting from six genotypes (i.e. ε2/ ε2, ε2/ ε3, ε2/ ε4, ε3/ ε3, ε3/ε4 and ε4/ ε4) [9] . The sequence variations found between APOE isoforms induce structural modifications of the apoE protein that ultimately modulate low density lipoprotein receptor family (LDL-R) binding activity [10] . The structural conformation of apoE4 explains its preferential bind to triglyceride rich lipoproteins (i.e. VLDL and LDL) as opposed to apoE3 and apoE2 which preferentially bind to high density lipoproteins (HDL) [10, 11] . Therefore, E4+ subjects usually have higher plasma triglycerides (TG), total cholesterol, and small and dense LDL than E4− [10, 12] . Because apolipoprotein E (apoE) plays important roles in the regulation, transport and clearance of fatty acids, carrying apoE4 isoform may modulate the efficiency of apoE in accomplishing its essential role in lipoprotein metabolism. Moreover, the lack of protection against CHD M A N U S C R I P T
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and AD when E4+ are supplemented with n−3 PUFA may potentially be explain by a disrupted postprandial kinetics of dososahexaenoic acid (DHA; 22:6 n−3), an n−3 PUFA [7] . Other studies reported gene-by-diet interaction in the uptake of n−3 PUFA and cholesterol metabolism in E4+ supplemented with 3 g/d of n−3 PUFA [4, 12, 13] .
Because E4+ supplemented with n−3 PUFA have greater sensitivity of fasting triglycerides [14] and increased total cholesterol [4, 13] when compared to E4− subjects, we speculate that n−3 PUFA distribution in plasma lipoproteins is APOE isoformdependant. We also hypothesize that n−3 PUFA are mainly incorporated into LDL particles in E4+ subjects as opposed to HDL particles in E4− carriers. The aim of this study was to determine the longitudinal FA profile in the HDL and LDL of young E4+
and E4− participants receiving 680 mg/day of DHA + 900 mg/d of eicosapentaenoic acid (EPA; 20:5 n−3) over a 4-weeks intervention.
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MATERIAL AND METHODS
Subjects and study design
Eighty-two healthy men and women (N = 82) aged between 20−35 years old, from the Sherbrooke area, were recruited. Subjects were excluded if they smoked, were medicated, with the exception of contraception pills, had a history of psychiatric difficulties or depression, were allergic to seafood, were pregnant or breastfeeding, or were already supplemented with n−3 PUFA capsules. Each participant gave their informed written consent before participating in the study. This study was approved by the ethics committee of the Health and Social Services Center, Sherbrooke University Geriatrics Institute. This study is registered in clinicaltrial.org (NCT-01544855).
Participants were asked to consume two capsules of ethyl ester fish oil (450 mg of EPA + 340 mg of DHA/capsule) daily for 4 weeks (Ocean Nutrition, Dartmouth, NS, Canada). This dose corresponds to three times the current n−3 PUFA consumption in young French Canadian adults [15] . Participants were instructed to record their daily consumption of fish, alcohol and natural products in a logbook. Compliance was measured by counting the capsules returned to the research staff each week.
Participants came to our research facility once per week, for 4 weeks, and a fasted blood sample was collected. Plasma was separated from red and white blood cells by centrifugation (3500 g during 10 min at 4°C). Whole blood was kept for subsequent DNA extraction and APOE genotyping. Separation of HDL and LDL was performed as follows: 800 µL of plasma was added to a sucrose gradient as described in Cooper et al.
[16]. Briefly, 105 mg of sucrose was added to plasma to obtain 12.5% of sucrose in plasma. The sucrose gradient was created by successive layers, from top to bottom: 500 M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT µL of PBS, 12.5% of sucrose + plasma, and 333 µL of both 25% and 47% sucrose in PBS solutions (w/w). Ultracentrifugation was performed at 201 000 g, 12°C during 26 h using a Beckman Optima TLX ultracentrifuge equipped with a TLS-55 rotor (Beckman Coulter, Brea, California, United State). The following fractions were pooled together: 700 µL of LDL (fraction 3−9, ρ=1.04-1.07 g/mL) and 600 µL of HDL fractions (fraction 10−15, ρ=1.07-1.23 g/mL). Blood biochemistry including glucose, albumin, total cholesterol (TC), TG, thyroid stimulating hormone (TSH), aspartate transaminase (AST), alanine transferase (ALT), HDL-cholesterol (HDL-C), LDL-cholesterol (LDL-C) and creatinine was assessed at the Centre Hospitalier Universitaire de Sherbrooke.
Fatty acid analysis
FA profile of HDL and LDL particles was performed as previously described [17] . Briefly, total lipids were extracted from HDL and LDL using a 2:1 chloroform: methanol solution. The total lipid extract was then saponified using 1M KOH/methanol and heated at 90°C for 1 h, thereby releasing the FAs from cholesteryl esters and glycerolipids. The transmethylation of FA into FA-methyl-esters was done by adding boron trifluoride/methanol (14%; Sigma-Aldrich, St-Louis, Missouri, USA) and were heated at 90°C during 30 min. Analysis was performed using a gas chromatograph 
Statistical analysis
Sample size calculation was based on the relative percentage of DHA in plasma TG at baseline in E4+ (0.82% ± 0.25%) and E4− (0.53% ± 0.31%) as reported in Plourde et al [8] . This metric was used since no data are currently available in literature on baseline-DHA content of HDL or LDL according to APOE genotype. An unequal sample size in each group was expected for two reasons: 1) our institution does not allow prescreening for E4+ genotype; 2) 15-25% of Canadians are known to be carriers of at least one epsilon 4 allele of APOE [18] . To achieve a statistical power of 80% (α = 0.05), we determined that ten (N = 10) E4+ were needed. Therefore, based on the lowest frequency of APOE epsilon 4 allele in Canadians (15%), the number of participants to be recruited Univariate spearman correlation analysis was used to investigate associations among outcome. The balance of n−6/n−3 PUFA was calculated using the sum of the following FA: the sum linoleic acid (LA), di-homo-gamma linolenic acid (DGLA), and arachidonic acid (AA) over the sum of alpha-linolenic acid (ALA), EPA, docosapentaenoic acid (DPA), and DHA. P values ≤ 0.05 were considered statistically significant, and P value for trends was set as ≤ 0.08. FA profiles are presented as means percentage (%) of total FA ± SEM and as percentage (%) compared to control, meaning E4-subjects, using the following equation:
RESULTS
Participants
The characteristics of E4+ and E4− are presented in Table 1 . Ten participants were carrying one allele of E4+ (N = 6, ε4/ε3 and N = 4, ε4/ε2) whereas the remaining participants were classified as E4− (N = 59, ε3/ε3 and N = 11, ε3/ε2). There were an equal number of men and women in the E4+ group, whereas men represented 41% of the E4− group. Two individuals were ε2/ε2 and were excluded from our statistical analysis to avoid any bias since APOE2 homozygous commonly have dyslipidemia [9] . There was no significant difference in baseline anthropometrics values, alcohol consumption or physical activity levels between both groups. Consumption of fish oil was well tolerated by the participants.
Variation of biomarkers between baseline and week 4
As shown in Table 2 , there was a genotype × time interaction (P = 0.021) for albumin and for creatinine (P = 0.047), a biomarker of kidney function. There was an independent genotype (P = 0.022) and time effect (P = 0.021) on HDL-cholesterol (HDL-C). E4+ had 20% higher HDL-C level at baseline (P = 0.015) when compared to E4−.
Four weeks after starting the supplement, total-C/HDL-C ratio was significantly reduced in both groups (P = 0.029) without any genotype effect. Total-C tended to be higher in E4+ independently of time (P = 0.057).
Fatty acid profile in HDL according to APOE-genotype
At baseline, there was no significant difference in the lipid profile of HDL according to genotype (Table 3 ). There were significant genotype × time interactions for M A N U S C R I P T
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16:0 and 18:2 n−6 in HDL. There was an independent time effects on EPA and DHA.
Levels of EPA and DHA reached a plateau within 2 weeks of supplementation with n−3 PUFA. At week-4, the n−6/n−3 PUFA ratio tended (P = 0.062) to be higher in E4+ subjects compared to E4− ( Figure 1A) . Baseline DHA in HDL was positively correlated to baseline HDL-C (r = 0.400, P <0.001) and week-4 DHA in HDL to week-4 HDL-C (r = 0.206, P = 0.046) in E4− subjects only.
Fatty acid profile in LDL according to APOE-genotype
Baseline 16:1 n−7 and DHA were 29% and 19% lower, respectively in the LDL of E4+ compared to E4− (Table 4 . At baseline, the n−6/n−3 PUFA ratio was 17% higher in the LDL of E4+ than E4− ( Figure 1B ). There was a genotype effect for 16:1 n−7 and ALA. There was a time effect for 18:1 n−9, EPA (P < 0.001) and DHA (P < 0.001) (Table 4) . At week-4, n−6/n−3 PUFA ratio was 31% higher in the LDL of E4+ compared to E4− ( Figure 1B ). There was no statistically significant correlation between EPA or DHA in LDL and LDL-C, nor at baseline or at week-4.
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DISCUSSION
Contrary to what we anticipated, n−3 PUFA in the HDL and the LDL were not APOE isoform-dependant in young participants, before and after n−3 PUFA supplementation. N−3 PUFAs were similarly incorporated into plasma LDL and HDL of E4+ and E4− subjects. However, there was a genotype × time interaction for 16:0 and 18:2 n−6 in the HDL. N−6/n−3 PUFA ratio in the LDL faction of E4+ was significantly higher than E4-, both at baseline and at 4-weeks. Thus, the APOE isoform-dependant distribution of FA into HDL and LDL particles was more subtle than we anticipated.
Absence of genotype × time interactions may be related to the young age of our participants (25-35 years old) compared to prior studies [12, 13, 20] . Calvalho-Wells et al [12] showed that disturbance in cholesterol and TG metabolism was only in E4+ aged over 50 years old. Similarly, n−3 PUFA metabolism seems to be age-dependant [21] and DHA kinetics is modified by age [22] .
In this study, there was higher n−6/n−3 PUFA ratio (P = 0.048) in the LDL of E4+ compared to E4− which arises from a tendency towards lower baseline-DHA, without significant changes in n−6 PUFA. There are two potential reasons explaining this result: 1) lower dietary intake of n−3 PUFA in the E4+ group or 2) imbalance in n−3 PUFA metabolism as supported by our previous studies [7, 8] . Unfortunately, nor food frequency questionnaires nor 3-d dietary intake recall were administered to participant, thus we can't discard that E4+ subjects may have taken a diet lower in n−3 PUFA. The importance of the n−6/n−3 PUFA ratio is currently a source of debate in determining the risk of CVD [23, 24] . Harris et al [23] concluded that the n−6/n−3 PUFA ratio may be a poor biomarker of the risk of CVD compare to the n−3 PUFA profile alone. However, M A N U S C R I P T
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Simopoulos [25] argue that this ratio is an important factor to consider in primary and secondary prevention of CVD. The higher n−6/n−3 ratio in the LDL of E4+ is therefore potentially contributing to higher CVD risk as reported in literature [4, 11, 26] , but this needs to be investigated in another trial.
Previous studies reported that modulation of cholesterol metabolism is APOE isoform-dependant [12, 13, 20] . In this study, TG and LDL-C concentrations at baseline and at week-4 (Table 2) were both independent of genotype, probably because of the young age of the participants compared to other studies [12, 13, 20] . Contrary to previous studies [27] [28] [29] [30] , the E4+ of this study had higher levels of HDL-C at baseline and 4 weeks after receiving the n-3 PUFA supplement compared to E4− carriers ( Table 2) . This is potentially related to cultural differences between French Canadians and Europeans populations used in previous published studies (i.e. Lithuanian [27] , UK [28] and Finnish [29] ), but this thesis is only speculative and need further investigation.
We also reported a positive correlation between DHA in the HDL and HDL-C level, prior and after the supplementation, in E4− subjects only. This result is somewhat in line with Liang et al [30] , showing that APOE-allele modifies association between plasma phospholipid DHA and medium size HDL. N−3 PUFA supplementation seems to increase hepatic uptake of HDL-C in mice [31] and increase reverse cholesterol transport
[32], whereas homozygous mice for E4+ allele are less efficient at transferring apoA-I from VLDL to HDL, resulting in less HDL particles than APOE3 mice [20] . Moreover, the enriched-apoE VLDL particles associated to E4+ carriers are known to reduce lipase activity and thus diminish HDL synthesis [26] . Therefore, this association support that DHA may upregulate HDL production, explaining why E4-have higher levels of HDL-M A N U S C R I P T
C [27] [28] [29] [30] . However, contrary to E4-, there is no association between baseline-DHA in the HDL and HDL-C level in E4+ carriers. This result also supports the thesis of a disrupted lipid metabolism in E4+ carriers, but the exact mechanism needs to be clarified in future investigations. As emphasized by Liang et al [30] , the association between EPA or DHA with total cholesterol, LDL-C, and HDL-C is erratic and highly variable between clinical trials and thus, carefulness is needed while interpreting results for such investigation trials.
The lower levels of 16:0 and 16:1 n−7 in HDL and LDL of E4+ compared to E4− is an example of APOE isoform-dependant modification of FA distribution in plasma lipoproteins. As suggested in previous studies [7, 33] , this modification may result from a modulation of substrate preference (i.e. FA) undergoing β-oxidation in E4+ carriers. 
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This trial has strengths and limitations. The participants of this study were young age, therefore excluding bias induce by prescribed medication such as statins that are commonly taken in older E4+ individual for modifying lipoprotein metabolism [7, 12] .
Moreover, another strength is the low body mass index of participants (mean BMI <25 kg/m²), therefore limiting potential confounding effect between BMI and DHA kinetics [19] . There was an important intra-individual variation in FA distribution into plasma lipoproteins in E4+ participants, and this is potentially because the E4+ group included two APOE4 genotypes, namely ε4/ε3 (N = 6) and ε4/ε2 (N = 4). Indeed, a previous study reported that FA metabolism may be different between APOE4 genotypes (ε2/ ε4, ε3/ε4
and ε4/ ε4) [12] . Because of the small sample size of E4+ group (N = 10), it was not statistically possible to stratify our data according to these two APOE4 genotypes.
CONCLUSIONS
In conclusion, baseline level of n−3 PUFA, as well asn−3 PUFA level at 4-week after supplementation, were similar in HDL and LDL fractions of E4+ and E4− participants. This result suggests that disrupted DHA metabolism in E4+ is agedependant. Therefore, there is room to identify prevention strategies to prevent dysregulation of DHA homeostasis likely occurring in the older E4+. 
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Bold characters indicate significant differences (P ≤ 0.05). When interactions were found, significant P values for the independent genotype and time effects are indicated in parenthesis. 
When assumptions of homogeneity of the covariance matrixes were rejected (Mauchly's Test of Sphericity), Greenhouse-Geisser corrections were used. Bold characters indicate significant differences (P ≤ 0.05). When interactions were significant, P values for the independent genotype and time effects are indicated in parenthesis. 
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